Xvivo Perfusion AB stock analysis
Xvivo Perfusion AB (0RKL) Share Price & Analysis
0RKL Stock Chart & Stats
- Day’s Range
- SEK 202.80 - SEK 207.70
- 52-Week Range
- SEK 162.40 - SEK 314.00
- Previous Close
- SEK 202.40
- Volume
- N/A
- Average Volume (3M)
- 7,303
- Market Cap
- SEK 6.39B
- Enterprise Value
- SEK 6.74B
- Total Cash (Recent Filing)
- SEK 313.24M
- Total Debt (Recent Filing)
- SEK 120.61M
- Price to Earnings (P/E)
- 50.4
- Beta
- 1.46
- Next Earnings
- Jan 28, 2027 (Est.)
- EPS Estimate
- 0.87
- Last Dividend Ex-Date
- Mar 15, 2022
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Organic Growth
The broad-based growth indicates rising adoption of XVIVO’s transplantation technologies, especially in thoracic procedures. Strong sales expansion across the first nine months supports operating leverage, funds continued commercial investment, and strengthens the company’s position as transplant centers adopt advanced preservation workflows.
Regulatory And Product Expansion
Heart Assist Transport has achieved meaningful regulatory progress in Europe and the United States, expanding its addressable market beyond existing products. The broad EU indication and accepted U.S. application create a platform for future adoption, although commercialization remains dependent on approvals and reimbursement.
Financial Flexibility
Very low leverage gives XVIVO substantial financial flexibility to fund clinical trials, regulatory work, commercial expansion, and production capacity without relying heavily on debt. Recent positive cash generation further supports internal funding, even though the company’s longer-term cash-flow record has been uneven.
Bears Say
Component Constraints
Component shortages directly limit the company’s ability to convert customer demand into revenue, particularly in kidney products. Although management describes the issue as temporary, continued constraints over coming quarters could delay growth, weaken customer availability, and postpone the return to higher growth rates.
Margin And Services Pressure
Weak services revenue and negative services margin show that expansion of the surgical team and slower contract conversion are currently dilutive. Planned sales-force investment for future launches may create additional near-term margin pressure, making profitability less predictable while the growth infrastructure is built.
Customer Concentration Risk
A major customer’s planned partial move to an internal EVLP platform could reduce thoracic revenue and utilization of XVIVO’s products. Management expects new-customer growth to offset the impact, but the transition creates execution risk because replacement volume must be developed before the customer loss is fully absorbed.
0RKL FAQ
What was Xvivo Perfusion AB’s price range in the past 12 months?
What is Xvivo Perfusion AB’s market cap?
When is Xvivo Perfusion AB’s upcoming earnings report date?
How were Xvivo Perfusion AB’s earnings last quarter?
Is Xvivo Perfusion AB overvalued?
Does Xvivo Perfusion AB pay dividends?
What is Xvivo Perfusion AB’s EPS estimate?
How many shares outstanding does Xvivo Perfusion AB have?
What happened to Xvivo Perfusion AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Xvivo Perfusion AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Xvivo Perfusion AB
Xvivo Perfusion AB (publ) is a medical technology company that creates and supplies advanced solutions for the preservation and perfusion of organs, tissues, and cells, primarily for use in transplantation. The company's global reach extends across Sweden, the United States, both North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Its product line includes the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass system designed to facilitate safe normothermic ex vivo lung perfusion (EVLP). To support this, the XPS Disposable Lung Kit offers all the necessary sterile, pre-packed components for EVLP procedures. Xvivo also provides STEEN Solution, an optimally formulated buffered extracellular solution specifically for perfusing isolated donor lungs during EVLP. Additional offerings comprise Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte preservation solution, and the XVIVO Silicone Tubing Set, used for efficient flushing of donor lungs during the procurement process. The company also manufactures the XVIVO LS and XVIVO Disposable Lung Set, both critical devices for EVLP. Furthermore, Xvivo provides the XVIVO Organ Chamber, a sterile, single-use disposable container for temporarily housing isolated lungs before transplantation, and the XVIVO Lung Cannula Set, another sterile, single-use disposable medical product. Established in 1998, Xvivo Perfusion AB (publ) is headquartered in Gothenburg, Sweden.
- Sector
- General
- Industry
- Medical - Devices
- CEO
- Christoffer Rosenblad
- Employees
- 207
- Website
- www.xvivogroup.com
- Address
- MAessans gata 10, Mölndal, VG, 431 53, SE
Xvivo Perfusion AB (0RKL) Earnings & Revenues
0RKL Company Deck
0RKL Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall, with 32% organic Q3 growth, improving EBITDA and cash flow, strong thoracic and heart momentum, major European and U.S. regulatory progress, and multiple expansion opportunities. The main challenges were temporary component and manufacturing-transfer constraints, weaker services revenue and margins, uncertainty around a major U.S. lung customer, reimbursement timing in Europe, competition in U.S. Liver, and planned near-term commercial investment that is expected to cause a slight margin dip.
View all GB:0RKL earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 6 | 10 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 4 | 0 | 8 |
